Please login to the form below

Not currently logged in

MedImmune and Immunocore to join on melanoma trials

Will trial MEDI4736 in combination with tremelimumab

medimmune building 

AstraZeneca has revealed its biologics R&D arm MedImmune is to collaborate with Immunocore to conduct clinical trials in immuno-oncology.

Under the terms of the agreement, UK-based biotech Immunocore will conduct a phase Ib and II clinical trial combining MedImmune's investigational checkpoint inhibitors MEDI4736 and/or tremelimumab with IMCgp100, Immunocore's lead T-cell receptor based investigational therapeutic, for the potential treatment of patient with metastatic melanoma. 

The two companies will establish a dosing regimen for the combination within the phase Ib study. The phase II study will assess the safety and efficacy of the different combinations.

Dr Ed Bradley, senior VP and head of the oncology innovative medicines unit at MedImmune, commented: “We are pleased to expand our partnership with Immunocore, a leader in the discovery and development of novel T-cell receptor-based drugs, to include this combination clinical trial in melanoma.

“Immuno-oncology is a priority area for us and by employing combinations with biological synergies, we believe we have the potential to enhance treatment effectiveness and ultimately to see improved overall survival rates.”

MedImmune will have the first right of negotiation for the future commercial development of these combinations for tumour expressing glycoprotein 100, a tumour-associated antigen.

The firms already have a pre-existing research collaboration and licensing agreement to develop novel cancer therapies using Immunocore's Immune Mobilising Monoclonal T-Cell Receptior Against Caner (immTAC) technology.

Eliot Forster, CEO of Immunocore, added: “We are excited to deepen our relationship with MedImmune through this combination study agreement. 

“We look forward to a successful partnership in the development of novel combination treatments in metastatic melanoma, which we believe have the potential to be best-in-class treatments.”

Earlier this month, AZ's tremelimumab was granted orphan drug status for the treatment of malignant mesothelioma by the FDA.


Article by
Kirstie Pickering

21st April 2015

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company Conferences, Events and Exhibition Stands is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

Solaris Health looks at the gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...